VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Apimeds Pharmaceuticals US, Inc (APUS) Total Return Calculator with Dividends Reinvested

Apimeds Pharmaceuticals US, Inc

Popular:

The total return for Apimeds Pharmaceuticals US, Inc (APUS) stock is -33.18% over the past 12 months. So far it's down 11.98% this year. The 5-year total return is -33.18%, meaning $10,000 invested in APUS stock 5 years ago would be worth $6,682 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in APUS 1 year ago, it would be worth $6,682 today — you'd have lost $3,318.

With Dividends Reinvested$6,682-33.18%

Price Only (No DRIP)$6,682-33.18%

Period2025-05-09 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in APUS

1Y$6,682-$3,318 (-33.2%)-33.2% CAGR

3Y$6,682-$3,318 (-33.2%)-12.6% CAGR

5Y$6,682-$3,318 (-33.2%)-7.7% CAGR

10Y$6,682-$3,318 (-33.2%)-4.0% CAGR

15Y$6,682-$3,318 (-33.2%)-2.7% CAGR

20Y$6,682-$3,318 (-33.2%)-2.0% CAGR

30Y$6,682-$3,318 (-33.2%)-1.3% CAGR

Apimeds Pharmaceuticals US, Inc did not pay dividends during this period. Total return = price return.

Loading APUS total return...

As of 2026-05-08

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-11.98%	—	-11.98%	—	$8,802
1Y	-33.18%	-33.18%	-33.18%	—	$6,682
3Y	-33.18%	-12.58%	-33.18%	—	$6,682
5Y	-33.18%	-7.75%	-33.18%	—	$6,682
10Y	-33.18%	-3.95%	-33.18%	—	$6,682
15Y	-33.18%	-2.65%	-33.18%	—	$6,682
20Y	-33.18%	-2.00%	-33.18%	—	$6,682
30Y	-33.18%	-1.33%	-33.18%	—	$6,682

Risk & Highlights

Best Year-25.45%2025

Max Drawdown-71.79%2025-11-17 → 2026-02-12

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-18.32%	-18.32%	—	+0.41%	-18.7pp
2025	-25.45%	-25.45%	—	+16.64%	-42.1pp

APUS underperformed the S&P 500 by 63.55pp over the past year (-33.18% vs +30.37%).

Loading summary...

APUS Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
APUSApimeds Pharmaceuticals US, Inc	$16M	-21.8%	-12.0%	-33.2%	—	-33.2%	-33.2%	-33.2%
HALOHalozyme Therapeutics, Inc.	$7.7B	+2.5%	-7.3%	-7.1%	—	+115.3%	+37.0%	+570.7%
ACRSAclaris Therapeutics, Inc.	$586M	+29.6%	+68.8%	+288.8%	—	-42.1%	-78.8%	-76.3%
SLRXSalarius Pharmaceuticals, Inc.	$697,790	—	+13.3%	-93.1%	—	-99.7%	-100.0%	-100.0%
NUVBNuvation Bio Inc.	$1.7B	+6.9%	-43.8%	+136.3%	—	+197.5%	-58.3%	-51.8%
PRGOPerrigo Company plc	$1.6B	+11.0%	-13.5%	-51.2%	+4.4pp	-58.1%	-60.1%	-77.7%
PAHCPhibro Animal Health Corporation	$1.7B	-22.5%	+16.0%	+125.1%	+2.5pp	+210.4%	+66.0%	+128.6%
CRLCharles River Laboratories International, Inc.	$9.0B	+7.3%	-10.1%	+32.8%	—	-4.2%	-46.9%	+119.2%
IQVIQVIA Holdings Inc.	$30.3B	+4.7%	-20.7%	+16.5%	—	-5.9%	-23.8%	+166.5%
MEDPMedpace Holdings, Inc.	$12.2B	-15.7%	-24.9%	+42.9%	—	+104.6%	+159.4%	+1442.7%
ICLRICON Public Limited Company	$9.5B	+16.6%	-33.7%	-10.0%	—	-34.1%	-45.4%	+91.0%

Compare:APUS vs HALO APUS vs ACRS APUS vs SLRX APUS vs HALO vs ACRS

About APUS Dividend Returns

Apimeds Pharmaceuticals US, Inc (APUS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of APUS over the past year?

Apimeds Pharmaceuticals US, Inc (APUS) delivered a return of -33.18% over the past year. Since APUS does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in APUS be worth today?

A $10,000 investment in Apimeds Pharmaceuticals US, Inc one year ago would be worth $6,682 today, representing a loss of $3,318.

Q3Does APUS pay dividends?

Apimeds Pharmaceuticals US, Inc (APUS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For APUS, the total return equals the price-only return.

Q4Did APUS beat the S&P 500?

No, Apimeds Pharmaceuticals US, Inc (APUS) underperformed the S&P 500 by 63.55 percentage points over the past year. APUS delivered a total return of -33.18%, compared to the S&P 500's 30.37%. This means a passive S&P 500 index fund outperformed APUS by 63.55pp during this period.

Q5What is APUS's worst drawdown?

Apimeds Pharmaceuticals US, Inc (APUS) experienced a maximum drawdown of -71.79% over the past year, declining from its peak on 2025-11-17 to its trough on 2026-02-12. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is APUS's long-term total return over 10, 20, or 30 years?

Here are Apimeds Pharmaceuticals US, Inc (APUS)'s long-term returns with dividends reinvested. Over 10 years, the total return is -33.2% (-4.0% CAGR) — $10,000 would have grown to $6,682. Over 20 years: -33.2% total return (-2.0% CAGR) — $10,000 → $6,682. Over 30 years: -33.2% total return (-1.3% CAGR) — $10,000 → $6,682. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.